MedTrace Logo

A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma

NCT04324840 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 184

Last updated 2024-07-26

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and tolerability of CC-90010 when combined with standard of care treatment, temozolomide (TMZ) with or without radiotherapy (RT) in the newly diagnosed WHO Grade IV glioblastoma (ndGBM).

Conditions

Interventions

DRUG

CC-90010

Specified dose on specified days

DRUG

Temozolomide

Specified dose on specified days

RADIATION

Radiotherapy

Specified dose on specified days

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-10
Primary Completion
2024-07-09
Completion
2024-07-09

Countries

  • United States
  • Denmark
  • Italy
  • Netherlands
  • Norway
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04324840 on ClinicalTrials.gov